Objectives.-To compare the interviewer-administered Quality of Well-being Scale (QWB) with a self-administered form (QWB-SA) for patients with migraine, and to compare the health status of migraineurs to other medical populations.
work and impairment of work activities, reduced social/ recreational activities, and poor mental health. [1] [2] [3] Quantifying this burden of illness can help determine the benefits of treatment at both a clinical and a societal level. [4] [5] [6] A consensus report from US Department of Health and Human Services (DHHS) agencies (including the National Institutes of Health, Agency for Health Care Policy and Research, Health Care Financing Administration, and others) urged the evaluation of cost-effectiveness of health care interventions using a common methodology. 7 The DHHS report noted that cost-effectiveness analysis (CEA) requires a common metric, such as dollars per quality-adjusted life-year (QALY). 8 The Canadian guidelines for pharmacoeconomic analyses 9 also recommend the use of QALYs or instruments able to measure across diseases and programs as the preferred outcome measure in CEA. These metrics are built upon generic, preferenceweighted measures of health status. The use of a measure that produces information used in calculating QALYs would help demonstrate the true burden of migraine at a societal level and help in resource allocation decisions.
One measure that can be used to calculate QALYs is the Quality of Well-being Scale (QWB). 10 The QWB is a preference-weighted measure combining three scales of functioning with a measure of symptoms and problems to produce a point-in-time expression of well-being that ranges from 0 (for death) to 1.0 (for asymptomatic full function). Several studies have compared the QWB to the most common measure of health-related quality of life (HRQOL), the Medical Outcomes Study (MOS) Short Form-36 (SF-36), 11 and some conclusions can be drawn.
12 Table 1 summarizes characteristics of the SF-36, the QWB, and the self-administered version of the QWB (QWB-SA). 13 As can be seen in Table 1 , there are a number of drawbacks to both the SF-36 and the QWB. One significant limitation of the QWB has been the relative expense to use an interviewer-administered instrument. An important limitation of the SF-36 is that it does not produce a metric that can be used in cost-effectiveness analyses. We believe the QWB-SA addresses both these limitations. 14 The interviewer-administered version of the QWB has been used in numerous clinical trials and population-monitoring studies. 5, 8, 15 Earlier work suggested biases in an early self-administered format, [16] [17] [18] yet recent refinements in questionnaire design have helped to circumvent and/or minimize these problems. The QWB-SA appears to have good test-retest reliability, 14, 19, 20 adequate discriminant validity in a variety of illness populations, 21, 22 and sensitivity to outcomes of cataract surgery, 23 and to severity of mental illness. 24, 25 The specific aims of the current study are to assess the sensitivity of the QWB-SA to detect changes in HRQOL of migraineurs as a function of migraine and to compare the HRQOL of migraineurs to that of medical clinic patient groups.
METHODS
Subjects.-A total of 100 adults living in Canada known to suffer migraine were approached by a market research firm to participate in the study and provided informed consent. All subjects were 18 years of age or older, spoke English as their primary language, were available to complete periodic telephone interviews, and reported a history of two or more migraines per month on average. All subjects were compensated $30 after agreeing to participate and an additional $30 upon completion of the study. Only the 89 participants who competed all study assessment instruments during at least one of three assessment periods were included in the analyses reported here. A comparison of the 89 participants with the 11 excluded from analyses found no differences on age, gender, or migraine frequency. Of the 89 participants, 77 (87%) were women, with the mean age of 42.2 Ϯ 9.8 years (range, 36 to 64 years).
Procedure.-Each subject was instructed on the study protocol, signed a consent form (this study was approved by the University of California, San Diego [UCSD] IRB), and was provided with study materials. Each subject was asked to complete three different assessment instruments (described below). For the first assessment, participants were instructed to complete a QWB-SA during a time in which no migraine was experienced in the previous 7 days, mail the questionnaire in the envelope provided to them, and then call the UCSD Health Outcomes Assessment Program's toll-free line to schedule a telephone-administered QWB interview and complete that interview within 2 days. The second and third assessments each were completed within 48 hours of the onset of separate migraines and included completion of all three instruments. The order in which participants completed these instruments, on each of three occasions, was counterbalanced. That is, half the participants completed the QWB-SA first, followed by the QWB; the other half completed the QWB first, followed by the QWB-SA. Since each instrument covers a time period of 3 (QWB-SA) or 6 (QWB) days, there were to be both migraine and nonmigraine days covered in each of the final two assessments.
Instruments.-Quality of Well-being Scale. -The QWB 10 is a generic HRQOL instrument that was designed for use in CEA. The output from the QWB is an index score between 0.0 (death) and 1.0 (perfect health). The QWB includes a symptom scale and three scales of function: mobility, physical activity, and social activity. Each symptom and step on these scales has its own associated preference weight. The overall QWB score is based on a preference-weighted average of functioning in the previous 6 days with respect to symptoms and the three function scales. For this study, scores were computed for each day separately to allow aggregation based on migraine status. The QWB has been shown to be reliable, internally consistent, correlate with a wide variety of medical and psychosocial variables, and the preference weights have been shown to be stable across patient groups and over time. 8, 10 Quality of Well-being Scale, Self-administered. -The QWB-SA 13 format is similar to the interviewer version, in that it includes a symptom scale and three scales of functioning: mobility, physical activity, and social activity. The primary differences are the mode of administration, respondents are asked to report on only the previous 3 days, and there are an increased number of mental health items in the symptom/problem subscale, resulting in a total of 77 items. It takes an average of 11 minutes to complete the entire questionnaire. Initial studies have demonstrated good psychometric properties of the QWB-SA. 14, 19, 20 In ad- QWB indicates Quality of Well-being Scale; QWB-SA, Quality of Well-being Scale, Self-administered.
dition, the QWB-SA was found to be sensitive to clinically significant change in patients with depression 24 as well as change in patients after cataract surgery. 23 Migraine Intensity Questionnaire. -This questionnaire has been used as a primary endpoint in clinical trials of several pharmaceutical products. 26 A copy of the 5-question instrument is in the Appendix.
Analytic Methods.-Within-subject analysis of variance (ANOVA) was performed on all continuous variables when comparing the two instruments used in this study, and between-subject ANOVA when comparing two or more independent groups. Intraclass correlations were used to assess the test-retest reliability comparing the first assessment (nonmigraine days) to the second and third assessments (nonmigraine days); the same was done when deriving this reliability during active migraine. Finally, Bonferroni corrections were used when multiple comparisons were performed.
RESULTS
A one-way ANOVA addressing the impact of order of questionnaire completion was not significant (F 1,88 ϭ 1.26, NS). Table 2 shows the number of completed assessments, by questionnaire version (self-administered and telephone interview) and by assessment time. As can be seen, fewer QWB-SA questionnaires were completed and returned by mail than QWB interviews completed by phone. According to the research design, assessments at time 2 and time 3 were to be completed subsequent to a migraine episode, with baseline assessments to be migraine-free. However, some subjects reported migraine during the baseline period while others reported no migraine during assessments time 2 and time 3. Therefore, all assessment periods were pooled and data for only those days on which health status was reported for both the QWB and the QWB-SA (ie, "matching days") are reported here. Each assessment could contribute up to 3 matching days, depending on the number of days of overlap between the 3-day QWB-SA assessment and the 6-day QWB assessment. Thus, a total of 621 days serve as the primary dataset. The unit of measurement is subject-day, with each subject contributing 6.98 subject-days/matching days on average.
A comparison between instruments was made to establish the rate of agreement for reporting migraines. Table 3 shows the days on which subjects reported a migraine on the QWB and QWB-SA. The between the two instruments was 0.85, reflecting a high rate of agreement above chance. It appears migraines were reported more often on the QWB-SA than on the QWB, but further study would be required to determine which instrument was actually more valid in this respect. That is, the higher frequency of migraines reported on the QWB-SA may reflect better recall of these events given the shorter window of recall or may reflect overreport of morbidity.
Test-retest reliability of the QWB-SA was calculated in the following manner: each subject's first nonmigraine day was paired with a nonmigraine day approximately 2 months (mean 63 days) after the initial assessment. A similar analysis was conducted across migraine days by constructing a pair of scores for each subject's migraine days, approximately 2 months apart (mean, 57 days). The resulting intraclass correlation for nonmigraine days was 0.74, while the correlation for migraine days was 0.51 ( P Ͻ .01). Table 4 shows the means for migraine and nonmigraine days for both the QWB and the QWB-SA. A two-way within-subject ANOVA used four observations on each subject (obtained by crossing QWB and QWB-SA with migraine and nonmigraine days). The analysis showed a significantly lower score for migraine days (as compared to nonmigraine days) for both instruments. The interaction term was nonsignificant, suggesting no significant difference between the instruments in the sensitivity of QOL given migraine status. (There was a main effect due to instrument, but this reflects the different weighting/scoring systems used for the two instruments.)
Additionally, we performed separate betweensubjects ANOVA on QWB-SA scores with pain and then disability 2 hours after taking medication as the independent variables in order to assess the sensitivity of the instrument. Table 5 shows mean QWB-SA scores by the reported intensity of the migraine experienced as well as self-reported disability. As can be seen, there is a linear trend for lower scores as reported migraine intensity increases (F 1,72 ϭ 5.3, P Ͻ .05) and as reported disability increases (F 1,72 ϭ 10.1, P Ͻ .01).
While overall scores on both measures were found to be lower during migraine days, further examination of which aspects of health status are affected is warranted. Therefore, we used within-subject paired t tests to compare migraine versus nonmigraine days separately on the four dimensions assessed by the QWB-SA: symptoms, mobility, physical activity, and social activity/self-care. Table 6 shows lower QOL and greater dysfunction on all dimensions during migraine days.
The QWB-SA has been completed for several specific population samples from various research studies coordinated by the UCSD Health Outcomes Assessment Program. Health status is often found to vary by age and gender. Eighty-seven percent of the sample were women, with an age range of 36 to 64 years, roughly approximating the demographics of this disease. 1 The composition of the comparison groups was adjusted to match this age and gender profile as closely as possible. The characteristics of the resulting comparison groups are shown in Table  7 . Family medicine clinic patients were evaluated at least 10 days postclinic visit in order to minimize bias of a sample of adults presenting with somatic complaints. Arthritis clinic patients were approached while waiting for a routine visit to their rheumatologist and completed paperwork within 7 days of their office visit. Ophthalmology clinic patients were all assessed within 3 weeks of a scheduled cataract surgery.
Using QWB-SA scores as comparison, Table 8 shows a relatively clear pattern. Following between- subject ANOVA showing significant differences between groups overall, Bonferroni-adjusted post hoc comparisons showed that migraineurs on migraine days reported similar scores to patients with arthritis and patients with cataracts (just prior to cataract surgery). The QWB-SA scores for migraine days were significantly lower than those for migraineurs on nonmigraine days and family medicine clinic patients. Table 9 shows a similar pattern when examining the individual component scores for all groups (in contrast to QWB-SA total scores, lower component scores indicate high QOL). Specifically, scores for symptom distress on migraine days were no different than those reported by patients with arthritis or patients with cataracts, but were significantly greater than nonmigraine days and for family medicine patients. For both physical activity and social activity/ self-care component scores, migraineurs reported greater dysfunction and lower QOL on migraine days than all other groups except patients with arthritis. No differences were found between any of the groups in mobility, namely driving an automobile nor being a patient in a hospital/nursing home; this is not surprising since all study groups were recruited from outpatient settings.
We have previously defined a constellation of mental health items on the QWB-SA. 24, 25 A QWB-SA mental health score is derived from a total of 11 items summed from each participant's QWB-SA responses, reflecting an array of mental health concerns (eg, anxiety, upset, irritability). Post hoc comparisons were then performed for migraine and nonmigraine days (Table 10 ).
An overall one-way ANOVA showed a significant difference between groups. Multiple group comparisons revealed significant differences between migraine days and all other groups except arthritis clinic patients.
COMMENTS
In helping to understand the humanistic impact of migraine and estimate the effectiveness of various interventions targeted at treating this condition, a general preference-weighted measure of HRQOL was used to quantify the personal burden of this illness. The QWB-SA was recently developed to address limitations in other popular health status instruments. The current study was designed to assess the instrument's sensitivity to change in health status, as well as to compare the impact of migraine relative to other medical conditions.
The findings reported here demonstrate the QWB-SA is sensitive to the presence and severity of migraine and suggests that the QWB-SA may have reasonable convergent validity as an outcome measure for patients with migraine. Similarly, low scores were found on both the QWB and the QWB-SA for migraineurs on migraine days as compared to migraine-free days. Scores on both instruments showed a linear decrease as patient-reported migraine severity increased. While the QWB-SA, a self-administered questionnaire that often takes less than 12 minutes to complete, may be more readily used in large clinical trials and epidemiologic research, results from this study are consistent with other reports that the rate of mail-back response is lower than investigator-initiated telephone interviews. As always, investigators must weigh methodological convenience with the importance of potential response bias in any particular study. However, the QWB-SA may be especially useful in assessment of migraine status given it demonstrated sensitivity to migraine intensity and the relatively extensive mental health symptomatology included, an aspect often reported to be impacted by migraines.
Results from this study help quantify the impact of migraines relative to other medical conditions. Specifically, patients report low HRQOL for days on which they suffer a migraine similar to patients presenting to an arthritis clinic. In fact, similarity in scores between migraineurs on migraine days and arthritis patients was found in the area of symptoms, physical activity, and social activity. The current findings also suggest that when not suffering a migraine attack, migraineurs report HRQOL scores similar to a cohort of patients presenting to a general medical clinic. While this comparison group completed the QWB-SA at least 1 week after presenting to a clinic, this population is likely to be less healthy than the general population. This pattern of similarity-migraine days similar to arthritis patients, nonmigraine days similar to general medical clinic patients-was also true for a measure of general mental health.
We caution the reader that there are significant limitations to this study. This work was completed on only a small number of patients with migraine. The subjects in this study were recruited from a Canadian metropolitan area and may not represent the general population of migraineurs. Another important limitation is that we do not know the nature of the migraines or the specific diagnosis. The data reported here are based exclusively on self-report. Although these data are preliminary, they do suggest that the generic QWB-SA may have value as an outcome measure for studies of migraineurs. With these limitations in mind, the current study shows promise for the QWB-SA to be used in larger trials of the impact of migraine and possibly help determine the cost-effectiveness of various interventions targeted toward treating this condition.
Several additional studies should be performed to establish the QWB-SA as a primary measure of outcomes in migraine populations. Such studies would help establish the measure's sensitivity to clinical improvement and further specify the areas of greatest impact from this often chronic, painful condition. The current results show the promise of this instrument in helping to document the burden of migraine to consumers in a cost-conscious world.
